NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 41

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated **July 30, 2007,**
1. LaPorte Hospital and Health Services Department of Nuclear Medicine	3. License number 13-15151-01 is amended in its entirety to read as follows:
2. 1007 Lincolnway LaPorte, IN 46350-0250	4. Expiration date March 31, 2014
	5. Docket No. 030-08653 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 8 curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (Bard Brachytherapy, Inc. Model No. STM 1251 and Theragenics Corp. Model No. 200 and I-seed Model 125.S06)	D. 2 curies
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed sources identified in 10 CFR 35.500 (North American Scientific Model No. MED 3601 or DuPont Pharma Model No. NES 8412 and Isotope Products Model HEG-137)	E. 400 millicuries
F. Depleted uranium	F. Stainless steel covered metal	F. 4 shields, not to exceed 12 kilograms each

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-15151-01

Docket or Reference Number
030-08653

Amendment No. 41

9. Authorized Use:

   A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

   B. Any imaging and localization study permitted by 10 CFR 35.200.

   C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

   D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

   E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

   F. Shielding in ADAC Laboratories MCD-AC attenuation correction system.

CONDITIONS

10. Licensed material may be used at the licensee's facilities located at 1007 Lincolnway, LaPorte, Indiana.

11. Radiation Safety Officer: James C. Hatten.

12. Licensed material is only authorized for use by, or under the supervision of:

   A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

   B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Hester Muller, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Russell Johnson, M.D.	10 CFR 35.100, 35.200, 35.300, 35.400 and 35.500.
Smari Thordarson, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Douglas J. Van Putten, M.D.	10 CFR 35.400.
John G. McGue, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
David A. Hornback, M.D.	10 CFR 35.300, 35.400 and 35.500.
Nina Fukunaga-Johnson, M.D.	10 CFR 35.300, 35.400 and 35.500.
Walter Edward Wojcicki, M.D.	10 CFR 35.100 and 35.200.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-15151-01

Docket or Reference Number
030-08653

Amendment No. 41

Toby S. Kramer, M.D.	10 CFR 35.400.
John E. DePersio, M.D.	10 CFR 35.100, 35.200, and 35.300 (**for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).**
Vivek Mishra, M.D.	10 CFR 35.100 and 35.200.
Richard Dobben, M.D.	**10 CFR 35.100, 35.200, iodine-131 for use under 35.300 and 35.500.**

13. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

    A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

    B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

    C. Sealed sources need not be tested if they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha-emitting material.

    D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

    E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

    F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-15151-01

Docket or Reference Number
030-08653

Amendment No. 41

15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license.

16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application received March 5, 2004;

    B. Letters dated June 9, 2005, October 14, 2005, November 1, 2006 and December 27, 2006;

    C. Facsimile letters dated September 6, 2005, September 8, 2005; and

    D. Facsimile (of e-mail) received February 15, 2007.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 07 2007

By _____
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III